



Index

```
abortion see termination of pregnancy
                                                 antepartum testing 135-6
achondroplasia 100
                                                 antimüllerian hormone (AMH)
activins 77-8, 79
                                                     developing follicles 68, 69, 77-8
adultery, concerns about 19-20, 22
                                                     ovarian reserve testing 80-1, 91-2,
advanced glycation end products (AGEs) 11
                                                       204, 205, 206
                                                 antioxidants 9
age
   of first intercourse 38
                                                 antral follicle count (AFC) 203-4, 205, 206
   maternal see maternal age
                                                 anxiety, infertile couples 265
   of menarche see menarche, age of
                                                 aortic dissection 154
                                                 ART see assisted reproductive technologies
   paternal see paternal age
ageing 3-13, 27-30
                                                 artificial insemination by donor see sperm
   cellular and molecular mechanisms
                                                   donation
                                                 assisted reproductive technologies (ART)
      9-12, 105-7
   concepts 8-9
                                                   203-301
   disease and 8-9
                                                     consensus views 353, 355
                                                     counselling older women 157, 164, 166
   ethnographic context 16–17
   evolution 6-8, 28
                                                     data collection priorities 356
   genetics 6-8
                                                     demographic aspects 60-1
   germ cell 12
                                                     feminist ethics 278
   population see population ageing
                                                     hypertension in pregnancy 145-6
   somatic 9-11
                                                     obstetric outcomes 125, 131, 135
age of childbearing
                                                     ovarian reserve testing 202, 205-6, 207
   changing patterns 35, 137, 186-7, 353
                                                     parenting outcomes 176-7
   economic aspects 342-3
                                                     paternal age effects 98
   optimal 138, 240, 353
                                                     risks in older parents 175
   political implications 341-5
                                                     services see infertility services
   public health messages on ideal 138,
                                                     sexual function after 267-8
      157, 163-4, 165, 240-1, 347-9, 353-4
                                                     single-embryo transfer 166-7, 310, 355
   see also maternal age; older mothers
                                                     single women 349
                                                     trends 187
age of menopause 39, 61
   changing patterns 186, 193
                                                     uses and abuses 227-34
   different cultures 16
                                                     see also in vitro fertilisation
   factors influencing 184, 193-5
                                                 autism, children of older fathers 101-2
   health in later life and 185, 196-7
                                                 autonomy 279
   longevity and 12, 13, 28-9
                                                 autophagy 106-7, 109-10
age-specific fertility rates 34-5
                                                 Avon Longitudinal Study of Parents and
Alzheimer's disease (AD), children of older
                                                   their Children (ALSPAC) 96, 111, 196
  fathers 102
American Society of Reproductive
                                                 baby boom 4, 33, 34
  Medicine (ASRM) 233, 237
                                                 baby gap 341-2, 343
andropause 95, 120
                                                 Baby M case 30
aneuploidies see chromosomal abnormalities
                                                 barrier contraceptive methods 252
```

Becker model of fertility choice 52	childlessness 331-7
birth cohort studies, British 39, 188, 196	adapting to 267-8, 332-3, 334-5
birth defects, paternal age and 101	counselling 335, 349
births	cultural aspects 18-19
numbers of live 33-4, 59, 340	long-term effects 333, 349
registration data 33, 60	political issues 339, 341
bleeding, obstetric 130, 131	social welfare implications 343
Blimp1 65, 322	statistics 36–7, 48, 61
BMP see bone morphogenetic protein	support networks 335-6
body	useful books 336
class differences in attitudes 21	see also infertility
social science perspectives 15-16, 17, 18	child mortality 3-4, 102
Body Shopping (Dickenson) 279, 288–9	child poverty 339, 343
bone mineral density (BMD) 185, 249, 251	children
bone morphogenetic protein-4 (BMP4)	born after new ART 356
65, 68, 69, 322	of obese mothers 149
bone morphogenetic protein-15 (BMP15)	of older fathers 101–2
68, 69, 77, 79	of older mothers 179–80, 195
Brazil 56, 59	China 56, 59
BRCA1/BRCA2 genes 282, 283-4, 287,	choice, language of 239
288	chromosomal abnormalities (including
breast cancer	aneuploidies)
genetically stratified screening 282–3	maternal age effects 12, 128, 227
	paternal age effects 101
genetic patents 283–4, 287	preimplantation genetic screening
in pregnancy 157 risk factors 185, 195, 249	
	229–30, 295, 355 chronic disease
British Fertility Society 166, 308	
British Society of Sexual and Relationship	future trends 187–8
Therapists 270	reproductive health predicting 184–5, 196–7
Caenorhabditis elegans 11	clinical trials, involving women 280–1
caesarean section 107–9, 111–12, 128, 134	clock genes 90
caloric restriction 11, 80	clomifene citrate challenge test (CCCT) 205
cancer	cloning 321, 325, 326, 329
ageing and 106	cohabitation 50
children of older fathers 101–2	combined hormonal contraceptives
oocyte cryopreservation 211, 216, 231	(CHCs) 249–50, 253
in pregnancy 155–7	complementary therapies, childless couples
reproductive function and 185	336
sexual function and 268	completed cohort fertility (CCF) 47
see also breast cancer	completed fertility rate (CFR) 47
cardiac disease	conception
maternal mortality 154	cumulative probabilities 50–1
maternal obesity and 149, 150	difficulties 175
·	, 2
see also coronary heart disease	rates 36
cardiovascular risk 185, 249–50	see also fecundity; fertility
careers, women's 342, 349	condoms 38, 245, 252
cell nuclear replacement (CNR) 321, 325	congenital anomalies, paternal age and 101
cell senescence 10–11, 105–6	connective tissue growth factor (CTGF) 77
Cerazette® 250–I	contraception 245–54, 354
cerebrovascular disease 250	barrier methods 252
see also stroke	class differences 21
childbirth, as cause of ageing 20	discontinuation 253-4
childcare 342, 343, 344–5, 347–8	emergency 253
childfree support networks 335–6	hormonal methods 247–52

methods for older women 246-53,	timing of motherhood and 175
273-4	trends 50, 51, 262
natural methods 252	DNA
religious ideas 22	damage 9, 10–11, 100–1
statistics 38	repair 9–10, 12
copper intrauterine devices (IUDs) 247,	doctor-patient relationships, power in 278,
253, 274	288
coronary heart disease	Down syndrome (trisomy 21) 101, 229
hormonal contraceptive users 249-50	
in pregnancy 153-5	early life factors, reproductive health 183-4,
reproductive factors predicting 147, 185	193-4
cost-effectiveness, infertility services 296–8,	Easterlin theory of fertility 52
308, 314–17	eclampsia 146, 147
counselling	economics
after failed fertility treatment 335, 349,	fertility 21-2, 51-3
355	infertility services 296-8, 308, 314-17
healthy age for childbearing 137-8,	late maternity 342–3
157, 163–4, 165	ectopic pregnancy 127–8
obstetric risks 168	educational status, fertility and 53
older women undergoing ART 157, 166	eggs see oocyte(s)
cryopreservation	embryo(s)
embryo 230	freezing 230
oocyte see oocyte cryopreservation	research using human 280, 325
ovarian tissue 215–16, 231, 239–40, 241	transfer, single 166-7, 310, 355
cryoprotective agents (CPAs) 212-13	embryoid bodies (EB) 325
culture 15–24, 30–1	embryonic germ (EG) cells 324
biology and 23	embryonic stem (ES) cells 323-4
ethnographic perspective 16–20	consent issues 325
variation within populations 21-2	derivation of gametes from 70-1, 321,
cybrids 280	324-5, 329
Cyprus 233	fibroblast-derived cells resembling 326
cytochrome P450 1A (CYP1A) 113–14	emergency contraception 253
, , ,	employment, women's 21, 53, 55, 342
data collection, priorities 356	endometrial cancer 185, 249
decidual ageing 112–13	environmental factors, ovarian ageing 80
degenerative disease 8-9	epidermal growth factor (EGF) 79
demographics 33-9, 59-62	epigenesis 65, 323
demographic transition 3-4, 55	erectile dysfunction 262-3, 269
second 50	estradiol, as marker of ovarian ageing 80,
see also population structure	205
Department of Health 303, 304, 305, 341	estrogen, myometrial ageing and 111-12
dependency ratios, population 340	ethics, feminist 278-9
Depo-Provera® 251	ethnographic context 15, 16-20, 30-1
depot medroxyprogesterone acetate	ethylene glycol 212, 219
(DMPA) 251	European Society of Human Reproduction
depression, infertile couples 266, 333	and Embryology (ESHRE) 230, 239,
diabetes 150-3	304, 305–6
antenatal care 153	evolution of ageing 6-8, 28
gestational see gestational diabetes	exogenous FSH ovarian reserve test
pre-existing 145, 151-2	(EFORT) 205
diaphragms, contraceptive 252	
dimethyl sulphoxide (DMSO) 212, 213, 219	
disposable soma theory 8, 10, 12, 13, 28	family planning 168, 245
divorce	see also contraception
age at menopause and 193	family size, ideal 48, 49

fecundity 50-1	fibroblast growth factor (FGF) 120
longevity and 12, 27	basic (bFGF) 69
paternal age effects 96-8	fibroblast growth factor receptor 3
female sterilisation 38, 245, 246	(FGFR3) 100
feminist ethics 278-9	Filshie clip 246
fertility	fitness, evolutionary 8
age-related decline 201, 227, 228	fluorescence in situ hybridisation (FISH) 229
availability of public information 341	follicles, ovarian
completed cohort (CCF) 47	antral 78, 79
life course approach 183-4	antral follicle count (AFC) 203-4, 205,
NICE guideline see National Institute	206
for Health and Clinical Excellence	atresia 66–7, 75, 76, 201
(NICE) fertility guideline	dynamics during ageing 66-8
political issues 339–45	establishment of reserve 65–6
see also fecundity; infertility	finite store 70, 75–6
fertility insurance 230–2, 237–41	lifespan 76–9
see also cryopreservation	primary 68
fertility poverty trap 342–3	primary-to-secondary progression 77–8
fertility prediction tests 206	primordial 66, 68
see also ovarian reserve testing	primordial-to-primary transition 68–9,
fertility rates 41–56	76–7
age-specific 34–5	recruitment 79
completed (CFR) 47	selection and dominance 79
determinants 49–54	follicle-stimulating hormone (FSH)
indicators 46–8	basal serum, ovarian reserve testing 80,
macro-level factors 51–3	203, 206
micro-level factors 49–51	detection of menopause 253–4
policy levers 53–4	follicular regulation 76, 77–8, 79
population projections and 340–1	FOXO3a (Foxo3a) 69, 77, 89
population structure and 4, 42	fractures, osteoporotic 185
projections 48–9, 54–6, 59, 60–2, 340–1	fragilis 322, 325
secular trends 33–5, 44–9	free radical theory of ageing 9
total see total fertility rate	freezing see cryopreservation
fertility trap hypothesis 48–9, 54	neezing see cryopieservation
fertility treatment	Gambia 20, 23
access to 332 consensus views 353, 355	gametes derivation <i>in vitro</i> 70–1, 321, 324–5,
counselling after failed 335, 349, 355	
	329–30
discontinuation 332–3 future demand 55–6	development in vivo 321–2, 323
	implications of using <i>in vitro</i> -derived
impact on ovarian ageing 67, 92 individualised 82, 89–90	325–6
	see also germ cells; oocyte(s); sperm
multiple births 36, 61	gay people 20
psychological effects 266	GDF9 68, 69, 77, 79
religious views 19–20, 22	gender issues
services see infertility services	fertility trends and 53
sexual relationships and 266–8	pay gap 342, 345
unrealistic expectations 331–2	views on infertility 19
fetal growth restriction 146	Genentech 284
fetal loss	genetic disorders, children of older fathers
maternal age effects 127–8, 129, 131–4,	100
227	genetic patents 283–4, 287, 288
potential interventions 135–6	genetics
see also miscarriage; stillbirths	ageing 6–8
fetal risks 175	ovarian ageing 79–80

genetic testing, breast cancer risk 282–3	surrogacy 20
germ cells	Human Embryonic Stem Cell
ageing 12	Coordinators (hESCCO) network 325
derivation from stem cells 70-1	Human Genetics Commission (HGC) 288
development 65, 321-2, 323	Hutchinson-Gilford progeria syndrome 10
embryonic 324	Hwang Woo Suk 280
primordial (PGCs) 321-2, 323	hypertension
see also gametes; oocyte(s); sperm	chronic 143-4, 145
germline 8	pregnancy-induced 143, 145-6
germline stem cells (GSCs) 65, 70	hypertensive disorders of pregnancy 143-7,
gestational diabetes 152-3	164-5
older mothers 128, 145, 152	future health consequences 146-7
ovum donation and 145, 153	maternal age effects 128, 130, 131
surveillance and intervention 136	maternal and fetal outcomes 146
glycation, protein 11	maternal obesity and 149, 150
gonadotrophin-releasing hormone (GnRH)	surveillance and intervention 136
agonist stimulation test (GAST) 205	see also pre-eclampsia
grandmother hypothesis, menopause 12–13,	hypoactive sexual desire disorder (HSDD)
28	264-5
grand multiparity 125	hypogonadism, late-onset 95, 120
granulosa cells	hysterectomy, sexual function after 268–9
apoptosis 76	nysterectony, sentan ranction after 200 y
growing follicles 68, 77–8	ICSI see intracytoplasmic sperm injection
primordial follicles 66	immigration 42, 59, 62, 341
growth-differentiation factor-9 see GDF9	Implanon® 252
gynaecological surgery, sexual function	implantation 112–13
after 268–9	imprinting
arter 200 g	disorders 175, 326
haploidisation, cellular 321	during gametogenesis 322, 325
hardiness, older mothers 176	incest 19–20
Hayflick limit 10	
health	income 52, 53, 342 incontinence surgery, sexual function after
children of older fathers 102	
	269 India 16–17, 21, 23, 56, 59
in later life, older mothers 183–9	
older people 6	induced pluripotent stem (iPS) cells 324,
heart disease see cardiac disease; coronary	326, 329–30
heart disease	induction of labour 135, 136–7
HELLP syndrome 146, 165	infertility 331–7
HER2 gene 284, 288	couple relationships and 226, 333
Herceptin® 284, 288	cultural perspectives 18–20
hormonal contraceptives, combined	impact on sexual function 265–8
(CHCs) 249–50, 253	psychological effects 266, 332–3
hormone replacement therapy (HRT)	religious ideas 19–20, 22
contraception during 251	secondary, ART provision 309
discontinuing contraception 254	see also childlessness; fertility
egg donation 233-4	Infertility Network UK (INUK) 295, 303,
health risks 185, 195	305, 307, 335, 344
trends in use 188	infertility services 293-301, 303-10,
Hulka-Clemens clip 246	313-17, 355
Human Fertilisation and Embryology	advice for women and doctors 298–300
Authority (HFEA)	age limits 296, 298, 307–8, 314, 315
egg donation 232-3, 237	class differences in access 21
in vitro-derived gametes 325	cost-effectiveness 296-8, 308, 314-17
IVF success rates 298–300, 309, 331	eligibility criteria 305, 308–9
single-embryo transfer 166, 310	future prospects 309–10

history of funding 303-5	keratinocyte growth factor (KGF) 69
implementation of NICE guideline	c-Kit 68
295-6, 305, 314-15, 353	Kit ligand (KL) 68, 69, 77
improving provision 306-7, 309, 354	Klf4 326
international comparisons 305-6	konenki 17, 30–1
NICE guideline see National Institute	Korean Womenlink 280
for Health and Clinical Excellence	Troteum Womenman 200
(NICE) fertility guideline	labour
Scotland, Wales and Northern Ireland	
	dysfunctional 107–9, 111–12, 134
313-14	induction 135, 136–7
see also fertility treatment	language, medical 23–4
information provision, on healthy age for	large bowel cancer 249
childbearing 138, 157, 163–4, 165, 240–1,	late-onset hypogonadism 95, 120
347-9, 353-4	legal aspects, surrogacy 29-30
inhibin B, serum 81, 204, 206	lesbians 20
inhibins	leukaemia inhibitory factor (LIF) 69
developing follicles 77–8, 79	levornorgestrel-releasing intrauterine
ovarian reserve testing 81, 91, 204	system (LNG-IUS) 247–9, 273–4
Institute of Psychosexual Medicine 269	life course approach 183–9
Institute of Public Policy Research (IPPR)	life expectancy 4
339, 340-1	healthy 6
insulin 11, 69	projections 54
intracranial haemorrhage 146	social class differences 4, 28
intracytoplasmic sperm injection (ICSI) 293,	trends 41-2
304	lifespan, stages 8
in animals 329	The Limits to Growth (Club of Rome) 41
NHS funding 316	lipofuscin 106, 109-10
paternal age effects 98	longevity
intrauterine devices (IUDs), copper 247,	age at menopause and 12, 13, 28-9
253, 274	DNA repair effectiveness and 10
intrauterine systems, hormonal 247–9,	fecundity and 12, 27
273-4	species specificity 6–7
in vitro fertilisation (IVF) 227-9, 293	low birthweight 128, 129
hypertension in pregnancy 145-6	luteinising hormone (LH) 79
maternal age and outcomes 228–9,	luteinising hormone/follicle-stimulating
294-5	hormone (LH/FSH) ratio test 205
multiple births 36	lysosomes 106
ovarian reserve testing 202, 205–6,	,
207, 295	male infertility, cultural perspectives 19
paternal age effects 98	male reproductive ageing 95–103, 119–20,
religious views 22	353
services <i>see</i> infertility services	cultural perspectives 17, 24
success rates 299–300, 331	see also older fathers; older men;
unrealistic expectations 331–2	paternal age
see also assisted reproductive	male sterilisation 38, 245, 246
technologies	marital relationships <i>see</i> relationships
ischaemic heart disease <i>see</i> coronary heart	marriage 49
disease	maternal age
Islam 19, 20, 22	at childbearing <i>see</i> age of childbearing
Israel 343–4	factors influencing 174–5
Italy 340	at first childbirth 41, 125, 126
IVF see in vitro fertilisation	IVF success by 228–9, 294–5
ivi see m vmv tertinsatiOff	at last childbirth 59–60
Japan 17–18, 23, 30–1, 340	obstetric interventions by 135–7
Jews, Hasidic 22	population implications 341–2
Je vv 5, 1 1451G1C 22	population implications 341 2

proportion of pregnancies by 141, 142 see also older mothers; older women	see also caesarean section morbidity, compression of 6
maternal maturity hypothesis (Hofferth) 176	More to Life 335
maternal mortality 141, 142, 163	mortality rates
cancer 157	reasons for decline 6
heart disease 154	trends 3-4, 41-2
hypertensive disorders of pregnancy	see also maternal mortality
146	mother hypothesis, menopause 12-13, 28
obesity and 149, 150	müllerian inhibiting substance see
maternity leave 343	antimüllerian hormone
media coverage	multiparity, grand (or great) 125
assisted reproductive technology 234,	multiple birth rates 35-6, 61, 187
303, 304	multiple pregnancy
egg freezing 231–2	assisted reproductive technology and
ideal maternal age 347, 348	166-7, 233
IVF clinic success rates 299	maternal age and 126
male reproductive ageing 95, 119	outcomes 128, 129, 130–1, 353
NHS provision of IVF 295	myocardial infarction 154–5, 249–50
older mothers 165, 332	myometrial ageing 107–13, 119
sexual function of older women 284	Myriad Genetics 283–4
· · · · · · · · · · · · · · · · · · ·	iviyilad Genetics 203–4
medical disorders of pregnancy 141–57,	Nama 222 222
163–9 Medical Research Council (MRC)	Nanog 322, 323
	National Infortility Assertances Compaign
National Survey of Health and	National Infertility Awareness Campaign
Development 39, 61	(NIAC) 304, 306
menarche, age of	National Institute for Health and Clinical
changing patterns 185–6	Excellence (NICE)
factors influencing 183–4, 194–5	breast cancer screening 282
health in later life and 184–5	Technology Appraisal (TA) programme
menopause	297
ageing theory 12–13, 28	National Institute for Health and Clinical
age of see age of menopause	Excellence (NICE) fertility guideline
cultural perspectives 16–18, 23–4, 30–1	293-4, 305, 313-17
discontinuation of contraception 253-4	advice for patients and doctors 295,
follicle dynamics 67–8	298–9
as pathology 27, 28	cost-effectiveness modelling 296-8,
premature 321, 353	308, 314–17
sexual function and 263-4	implementation 295-6, 305, 314-15,
see also ovarian ageing	332, 353
menstrual problems 246, 247, 248, 251	improving uptake 303, 306–7, 309, 354
migration, international 42, 59, 62, 341	planned review 310
Mirena® (levornorgestrel-releasing	natural family planning methods 252
intrauterine system; LNG-IUS) 247-9,	negative stereotypes 23-4
273-4	neonatal risks 175
miscarriage	Netherlands 344-5, 347
coping with childlessness after 334	neurodevelopmental disorders, children of
data collection needs 167, 356	older fathers 101–2
maternal age effects 127-8, 175, 227	neuroendocrine theories of ageing 11
paternal age effects 99	Newfoundland 18, 23, 30-1
mitochondrial DNA (mtDNA), damage 11,	NICE see National Institute for Health and
107	Clinical Excellence
mitochondrial theory of ageing 11	nodal 76
mode of delivery	non-compliance, patient 278
older mothers 107–9, 111–12	Northern Ireland, infertility services 313–1.
sexual function and 268	nutritional factors, ovarian ageing 80, 89



obesity	sexual problems 263-5
cultural concepts 21	oocyte(s)
future trends 187–8	age-related decline in quality 75, 90
maternal 147–50	aneuploidies 12
obstetric outcomes 125-38, 163-9, 175-6	apoptosis 65, 91–2
extremes of maternal age 134-5	derivation in vitro 70-1, 321, 324-5
health in later life and 185	development 65-6, 321-2
interventions to improve 135-7	dynamics during ageing 66-8, 201
maternal age effects 127–38	fetal, for egg donation 321
myometrial ageing and 107-9	finite store 70, 75–6, 92, 227
parity and 128-30	implications of using in vitro-derived
paternal age effects 99–100	325-6
plurality 130–1	oocyte cryopreservation (egg freezing)
plurality and ovum donation 131	211-21, 231-2, 295, 355
risk counselling 167–8	biological principles 211-15
study designs and pitfalls 125-7	clinical protocols 215–21
Oct4 322, 323, 324, 325, 326	cryoprotective agents (CPAs) 212–13
Oct4-GFP construct 70–1, 324	germinal vesicle (GV) stage 215, 216,
older fathers	219
children of 101-2	immature primordial stage 216
fetal and neonatal risks 99–101, 175	indications 211, 231–2
parenting outcomes 176–9	metaphase II (MII) stage 215, 216–21,
relationships 179, 194, 195–6	238
see also paternal age	slow-freezing (equilibrium) protocols
older men	213–14, 217–19
conception difficulties 96–8, 175	vitrification protocols 218–19, 219–21
exocrine testicular function 95–6	237-8
sexual function 260–1	warming protocols 215
sexual problems 262–3	see also ovarian tissue cryopreservation
see also male reproductive ageing	oocyte donation (egg donation) 232–3,
older mothers	295, 321
children of 179–80, 195	cultural perspectives 19–20
consensus views 354	donor risks 232
defining 173	ethical issues 231, 232–3
health in later life 183–9	financial incentives 233, 237
medical disorders of pregnancy 141–57,	gestational diabetes risk 145, 153
163–9	media coverage 165
obstetric outcomes 127–38, 163–9,	multiple birth rates 233
175-6	obstetric outcomes 131, 135
parenting 176–9	pre-eclampsia risk 145
personal attributes 173–5	single-embryo transfer 166–7, 355
relationships 179, 194, 195–6	stem cell research 279–80
risks to 175–6	
· =	surrogate pregnancy 20, 29–30, 234
trends 34–5, 137, 141, 142, 173	oocyte sharing (egg sharing) 231, 232–3,
see also age of childbearing; maternal age older women	237, 239
	oogenesis 65–6
contraception 245–54, 273–4, 354	operative delivery 107–9, 111–12
counselling on obstetric risks 168	oral contraceptive pill 38, 245
information on infertility services	combined (COC) 249–50
298–300	discontinuation 253
lack of research 280–1	progestogen-only (POP) 250-1
RCOG's relationship with 277–85,	uterine ageing and 117
287–9	osteoporosis 185, 248
reproductive risks 175–6, 245 sexual function 250, 260–1	Our Bodies, Ourselves (Boston Women's
sexual function 250, 200-1	Health Book Collective) 278

ovarian ageing	PCTs see primary care trusts
biomarkers 80-1, 91-2	pelvic infections 247, 273
environmental factors 80	perinatal mortality 128
genetic factors 79-80	PERSONA® 252
impact of ovarian stimulation 67, 92	phosphatidylinositol-3-kinase (PI3K)
inexorability 65-71, 353	signalling pathway 69, 76, 77
science 75-82, 89-93	placenta, ageing 105, 107, 113-14, 118
screening for early see ovarian reserve	placental abruption
testing	maternal age and 128, 130, 131, 134
silent premenopausal 201	pre-eclampsia and 146
slowing down 82, 89	placenta praevia 128, 130, 131
see also menopause	Poland 59
ovarian cancer 249	policies, government 53-4, 175, 339-46,
ovarian hyperstimulation 232	347-9
ovarian reserve testing 201–7, 238, 239, 240	polycystic ovary syndrome (PCOS),
assessing test quality 202	ovarian reserve testing 91, 203, 204
available tests 202–5	population
commercially available tests 206	decline 340–1
developing a screening strategy 207	growth 41
IVF 202, 205–6, 207, 295	political issues 339–45
multivariate models 205–6	population ageing 3–4, 41
rationale 201–2	implications 6, 42–4
ovarian stimulation, impact on ovarian	projections 5, 43
ageing 67, 92	population structure 3–4, 5, 43, 339
ovarian stromal blood flow test 205	determinants of change 41–2
ovarian tissue cryopreservation 215–16,	projections 43, 54–5, 60–2
231, 239–40, 241	relevance 42–4
ovarian volume measurement 205	see also demographic transition
ovaries, age-related shrinkage 75–6	poverty, early motherhood and 339–43
overprotective parenting 177	Prdm1 (Blimp1) 65, 322
ovum donation see oocyte donation	pre-eclampsia 143, 145–6, 164–5
oxidative stress 9, 11	
	future health consequences 146–7
oxytocin (Syntocinon®) 119	maternal age effects 128, 145 maternal and fetal outcomes 146, 167
paranting 176 0	
parenting 176–9	maternal obesity and 149, 150
research needs 194	superimposed on chronic hypertension
theories 177–8	144
parity	see also hypertensive disorders of
as confounding factor 107, 114, 118	pregnancy
obstetric outcomes and 125, 128–30	pregnancy-induced hypertension 143, 145-
sexual function and 268	see also hypertensive disorders of
patents, genetic 283-4, 287, 288	pregnancy
paternal age	preimplantation genetic screening (PGS)
assisted reproduction outcomes and 98	229–30, 295, 355
birth defects and 101	preschool care 342, 343, 344-5
birth outcomes and 99–100	preterm birth 128, 129
consensus views 355	plurality effects 130, 131
fecundity and 96–8	pre-eclampsia and 167
genetic disorders in children 100	primary care trusts (PCTs)
miscarriage risk and 99	age limits for ART 307-8
sperm DNA damage and 100–1	commissioning infertility services 303
see also male reproductive ageing; older fathers; older men	eligibility criteria for ART 308–9 implementation of NICE fertility
paternalism, medical 278, 281, 288, 289	guideline 295-6, 305, 314-15
paternity leave 343	improving provision of ART 306-7, 30
•	

```
primates, non-human 6, 27
                                                senescence, cell 10-11, 105-6
primordial germ cells (PGCs) 321-2, 323
                                                sex differentiation 322
progeria syndromes 7, 9-10
                                                 sexual function 259-70, 273
progesterone, myometrial ageing and 111-12
                                                    availability of evidence 259-60
progestogen-only emergency contraception
                                                    cancer patients 268
  (POEC) 253
                                                    gynaecological procedures and 268-9
progestogen-only implants 252
                                                    infertile couples 265-8
progestogen-only injectable contraceptives
                                                    older people 260-1
                                                    parity and mode of delivery and 268
progestogen-only pill (POP) 250-1
                                                    psychosocial issues 261-2
                                                    societal views 260
psychological effects, infertility 266, 332-3
psychosocial wellbeing
                                                sexual health 284
   older mothers 176
                                                 sexual intercourse, age at first 38
    sexual function and 261-2
                                                sexually transmitted infections (STIs) 284,
PTEN (Pten) 69, 77, 89
                                                   287, 353
puberty, follicle dynamics 66-7
                                                sexual problems 262-8, 354
public health burden 163, 167
                                                    classification 264
                                                    older men 262-3
public health messages, healthy age for
                                                    older women 263-5
  childbearing 138, 157, 163-4, 165, 240-1,
                                                    role of doctors 269-70
  347-9, 353-4
                                                sildenafil (Viagra®) 24, 284
quality-adjusted life years (QALY) 297,
                                                single-embryo transfer 166-7, 310, 355
                                                single women 49, 50, 348-9
  308, 314, 315
                                                 sir2 gene 11
                                                 SIRT1-7 genes 11
randomised controlled trials (RCTs) 296
reactive oxygen species (ROS) 9, 11, 107
                                                sirtuins 11
relational autonomy 279
                                                 smoking 154, 188
relationships (couple)
                                                social inequalities 339-40, 342-3
   infertile couples 266, 333
                                                social status, ageing women 17
   older parents 179, 194, 195-6
                                                social support 178-9
   sexual function and 262
                                                societal views, ageing and sex 260-1
   see also single women
                                                socio-economic differences
religious perspectives
                                                    life expectancy 4, 28
    contraception 22
                                                    reproductive function 183, 184
    infertility 19-20, 22
                                                    response to reproductive ageing 21-2
renal impairment 144
                                                soma 8
reproductive health/function
                                                    ageing 9-11
    changing patterns 185-7, 193
                                                    disposable see disposable soma theory
   chronic disease in later life and 184-5,
                                                Sox2 322, 323, 324, 326
      196-7
                                                sperm
    factors influencing 183-4, 193-4
                                                    derivation in vitro 325, 329
                                                    DNA damage in older men 100-1
reproductive tourism 233, 234, 240
                                                sperm donation
research
    involving women 279-81
                                                    cultural aspects 19-20, 22
    priorities, consensus views 355-6
                                                    upper age limit 355
   stem cell 279-80, 287-8
                                                spermicides 252
retirement 262
                                                 Stella 322, 325
Royal College of Obstetricians and
                                                 stem cell factor (SCF) see Kit ligand
  Gynaecologists (RCOG)
                                                stem cells 323-4
   recommendations for 353-4
                                                    ethics of research 279-80, 287-8
    relationship with older women 277-85,
                                                    induced pluripotent (iPS) 324, 326,
                                                    progress of research 325-6, 329-30
schizophrenia, children of older fathers 102
                                                    see also embryonic stem cells; germline
Scotland, infertility services 313-14
                                                      stem cells
```

INDEX | **367**

stepchildren 335 sterilisation, male or female 38, 245, 246 stillbirths maternal age effects 127-8, 131-4 placental ageing and 113-14, 118 potential interventions 135-6 in early life 184, 193-4 induced by children 195-6 infertility-related 266 stroke 144, 146, 250 sucrose 212, 213, 217-19 sugars, glycation of proteins 11 surrogacy 29-30, 233-4 cultural perspectives 20 gestational (donated eggs) 20, 29-30, 234 survival curves 6, 7 Sweden 49, 50, 53, 54 Syntocinon® (oxytocin) 119 telomerase 12, 106 telomeres, loss of 10-11, 105-6 termination of pregnancy infertility after 334 older women 36, 245 testicular ageing 95-6, 119 Test-Tube Women: What Future for Motherhood? (Arditti et al.) 278 theca cells, formation 77 time-to-pregnancy (TTP) 50-1 total fertility rate (TFR) 33-4, 44-9 adjusted (adjTFR) 47-8 European variations 44, 45, 46 tempo and quantum effects 46-7 see also fertility rates tourism, reproductive 233, 234, 240 transforming growth factor-beta (TGF-β) superfamily proteins 68, 76, 77-8, 79 trastuzumab (Herceptin®) 284, 288 trisomy 21 (Down syndrome) 101, 229 Tuareg people 21 tubal occlusion 246 Turner syndrome 80, 211, 330 UK Obstetric Surveillance System (UKOSS) 148, 155, 354 umbilical cord complications 134 unplanned pregnancy 245 urinary incontinence surgery, sexual function after 269 uterine ageing 105, 107-13, 117-19 vaginal dryness/dyspareunia 252, 263

vasectomy 38, 246
venous thromboembolism (VTE)
maternal obesity 149, 150
oral contraceptive pill users 250
veterinary science 329
Viagra® 24, 284
vitrification, oocyte 214–15, 219–21, 237–8
Waldeyer-Hartz (Waldeyer), HWG von 70
Wales, infertility services 313
Werner syndrome 7, 9–10

vascular disease 144